exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087808 RNA Name: hsa-miR-15a-5p RNA Type: miRNA Chromosome: chr13 Starnd: - Coordinate: Start Site(bp): 50049167 End Site(bp): 50049188 External Links: hsa-miR-15a-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand SPRYD3 chr12 53064316 53079404 - FAM89A chr1 231018958 231040254 - ZNF664 chr12 123971845 124015439 + ABCF3 chr3 184186023 184194012 + LITAF chr16 11547722 11636381 - GPR107 chr9 130053426 130140169 + CTTNBP2 chr7 117710651 117874139 - MED11 chr17 4731428 4733607 + ABHD2 chr15 89087459 89202355 + UNC119B chr12 120710458 120723640 + AADAT chr4 170060222 170091699 - KLHDC3 chr6 43014103 43021298 + JARID2 chr6 15246069 15522042 + ITPR1 chr3 4493345 4847840 + MAPK1IP1L chr14 55051647 55070194 + ANKRD17 chr4 73073376 73258798 - SRPK1 chr6 35832966 35921342 - STEAP3 chr2 119223831 119265652 + AMER1 chrX 64185117 64205708 - ASB1 chr2 238426742 238452250 + ARL1 chr12 101393116 101407772 - MRPS2 chr9 135499984 135504673 + SCAMP4 chr19 1905372 1926013 + ATXN7L3 chr17 44191805 44200113 - ZBTB34 chr9 126860665 126885878 + PLPP6 chr9 4662294 4665258 + ERG28 chr14 75649791 75660876 - TSPYL2 chrX 53082367 53088540 + ADGRL1 chr19 14147743 14206187 - TBL1X chrX 9463295 9741037 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001005 chr2 53921020 53978078 - hsa_circ_0001723 chr7 91924202 91948826 + hsa_circ_0000458 chr12 124071293 124074996 + hsa_circ_0001699 chr7 40027197 40041630 + hsa_circ_0001387 chr4 1902352 1936989 + hsa_circ_0001168 chr20 47691321 47707559 + hsa_circ_0000552 chr14 71880664 71948928 + hsa_circ_0000038 chr1 28800065 28802803 + hsa_circ_0000652 chr15 90984737 90986710 + hsa_circ_0001472 chr5 36953719 36976504 + hsa_circ_0001263 chr3 5215701 5216099 + hsa_circ_0000799 chr17 65941524 65972074 + hsa_circ_0001164 chr20 45891031 45923523 - hsa_circ_0000032 chr1 25666964 25669564 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand XIST chrX 73820649 73852723 - NEAT1 chr11 65422774 65445540 + NUTM2A-AS1 chr10 87201647 87342612 - AC021078.1 chr5 149494314 149504670 - SNHG25 chr17 64145970 64146476 + AC079781.5 chr7 97851688 97972985 - LINC02035 chr3 122886941 122892416 + LINC00662 chr19 27681072 27794005 - AL359924.1 chr1 237862175 237928321 + FGD5-AS1 chr3 14920347 14948424 - AC009022.1 chr16 69976297 70065948 - AC114980.1 chr5 93860669 93863825 - MZF1-AS1 chr19 58559129 58574797 + AL031282.2 chr1 1702736 1737688 - AC003092.1 chr7 94022833 94066661 + AC020978.7 chr16 68224713 68227734 + MIR497HG chr17 7015818 7019659 - AP000317.2 chr21 34073592 34360033 + AC002470.2 chr22 20979462 20998121 + HCG18 chr6 30286690 30327382 - MIR503HG chrX 134543119 134546642 - SNHG12 chr1 28578538 28583132 - NUTM2B-AS1 chr10 79661394 79826594 - LINC00649 chr21 33915534 33977691 + AC021092.1 chr19 44103007 44113183 - SNHG16 chr17 76557764 76565348 + SNHG1 chr11 62851984 62855953 - STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + MCM3AP-AS1 chr21 46229196 46259390 + MIR29B2CHG chr1 207801518 207879115 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.